Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs provides In Vivo CAR-T Engineering Solutions to address key challenges in cell therapy manufacturing, including the high cost of leukapheresis, complex ex vivo production bottlenecks, and the limited shelf-life of traditional cell products. This service enables direct programming of therapeutic T cells within the patient through advanced viral vector engineering and high-precision nanoparticle delivery platforms. By eliminating labor-intensive ex vivo processes, Creative Biolabs supports the transition from individualized manufacturing to scalable, off-the-shelf in vivo genetic medicines, accelerating the development and clinical translation of next-generation immunotherapies.
Traditional adoptive cell therapy is limited by the logistical burden of the living drug paradigms. In vivo engineering via viral or non-viral vectors can effectively reprogram autologous T cells into potent anti-tumor effectors. This method leverages the body's natural environment to maintain T-cell stemness and fitness. In conclusion, in vivo CAR-T engineering represents a transformative off-the-shelf solution that expands the reach of immunotherapy to solid tumors and autoimmune diseases globally.
Fig.1 In vivo CAR-T cells overcome many difficulties faced by conventional CAR-T.1
Leveraging extensive expertise in cell engineering, Creative Biolabs has established a CellRapeutics™ in vivo cell engineering development platform to support research in immunology and related biomedical fields. Our services utilize advanced technologies together with viral and non-viral delivery vectors to introduce therapeutic genes directly into the body, enabling the modification of immune cells.
Through optimized vector design, gene integration, and targeted in vivo delivery, we provide end-to-end customized solutions, from vector construction to functional validation, to meet the diverse needs of global researchers. By delivering the molecular machinery required to reprogram endogenous immune cells, our platform effectively transforms the patient's body into a localized bioreactor, achieving high transduction efficiency and sustained therapeutic activity while eliminating traditional vein-to-vein manufacturing delays and accelerating the development of life-saving therapies.
Discover How We Can Help - Request a Consultation.
Creative Biolabs provides a lentiviral vector platform that enables permanent genomic integration for the durable treatment of hematological malignancies. Advanced pseudotyping ensures precise T-cell targeting, while Tier-1 impurity control minimizes risks from random insertion and off-target infection.
Learn More →
Our tLNP-mRNA platform provides a non-integrative approach focused on safety and scalability, achieving up to 85% transduction efficiency with low risk of cytokine release syndrome. Its transient expression makes it well-suited for autoimmune diseases where precise dose control is essential.
Learn More →
This Targeted Integration Platform leverages Enveloped Delivery Vehicles (EDV) to deliver Ribonucleoproteins for precise TRAC locus cleavage and Adeno-Associated Virus vectors (AAV) for CAR template delivery. Using the endogenous TRAC promoter ensures physiological receptor expression, reducing cell exhaustion and enhancing long-term anti-tumor efficacy.
Learn More →Technical Comparison Table Choosing the right vehicle determines not just the efficacy of the drug, but its regulatory fate and commercial viability.
| Feature | Lentiviral Platform | tLNP-mRNA Platform | Targeted Integration |
| Integration | Random | None (Transient) | Site-Specific |
| Persistence | Permanent | Short-term | Permanent |
| Risk Profile | Insertion Mutagenesis | Minimal (Safe) | Optimized (Controlled) |
| Manufacturing | Complex | Streamlined | High Engineering Complexity |
| Primary Indication | Leukemia/Lymphoma | Autoimmune Diseases | Solid Tumors |
This deliverable includes a comprehensive analytical report with vector characterization, titration data, and in vitro/in vivo efficacy results; high-resolution raw sequencing and flow cytometry datasets for T-cell phenotyping and CAR integration site analysis; and a stabilized pilot-scale batch of the optimized engineered viral or non-viral delivery vehicle for further development.
Creative Biolabs provides in vivo CAR-T engineering services that enable direct genetic modification of T cells within the body, supporting efficient cell programming, scalable manufacturing, and improved therapeutic potential.
Learn More →Creative Biolabs offers in vivo B cell engineering to program antibody-producing cells directly in the body, enabling durable therapeutic protein expression and innovative immunotherapy strategies.
Learn More →We develop in vivo CAR-NK engineering platforms to generate functional CAR-NK cells within the body, enhancing innate immune targeting and expanding next-generation cell therapy options.
Learn More →Creative Biolabs provides in vivo CAR-macrophage engineering solutions to program macrophages for tumor recognition, phagocytosis, and immune modulation within complex tumor microenvironments.
Learn More →We enable in vivo engineering of PBMC populations, facilitating direct modification of immune cells to support flexible and scalable development of advanced cell-based immunotherapies.
Learn More →Q: How do you ensure the vector only targets T cells in vivo?
A: We utilize surface-engineered envelopes or ligand-functionalized nanoparticles that specifically recognize T-cell markers like CD3. This ensures the genetic payload is only internalised by the intended immune cells.
Q: Can we use mRNA instead of viral DNA for the CAR construct?
A: Our nanoparticle platform is optimized for mRNA delivery, which allows for transient CAR expression. This is particularly useful for managing safety and toxicity in early-phase research.
Q: What is the risk of off-target integration with viral vectors?
A: We employ integration-deficient or T-cell-specific viral systems and perform comprehensive integration site analysis to ensure safety and minimize the risk of insertional mutagenesis.
Q: Do patients need lymphodepleting chemotherapy for in vivo CAR-T?
A: One of the main advantages of our in vivo solutions is the potential to reduce or eliminate the need for toxic lymphodepletion, as the cells are programmed within their natural niche.
Creative Biolabs provides a revolutionary In Vivo CAR-T Engineering platform that replaces complex ex vivo manufacturing with precise in situ programming. Supporting everything from custom vector design to thorough in vivo validation, we offer a streamlined workflow for developing affordable, scalable, and highly potent immunotherapies. To learn more or discuss your project needs, please contact us. Our professional team is ready to assist with your customized requirements.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
